Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Almirall says it is delighted with Recordati agreement

Almirall says it is delighted with Recordati agreement

6th April 2009

Almirall is “delighted” to have reached an agreement with Recordati to co-market silodosin.

The Spain-based pharmaceutical company will work with the latter to advertise and sell the capsule that is designed to be taken once a day for benign prostate hyperplasia (BPH).

It reduces prostate enlargement symptoms by blocking alpha-1 adrenergic receptors in this organ, as well as in the bladder and urethra.

The arrangement will help strengthen its core business and Jorge Gallardo, chairman and chief executive officer of the firm, explained it would aid the high percentage of men who are affected by the condition in Spain.

“We ? are convinced that by incorporating silodosin into our product portfolio we will enhance our urology area while offering an efficient solution to improve quality of life for BPH sufferers,” he remarked.

Last month, Almirall released figures showing total revenues for 2008 were 136.1 million euros (123.5 million pounds) ? an increase of 3.8 per cent from the year before. Net sales also rose by 13.9 per cent to 902.8 million euros.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.